IP Verse

Elkington And Fife competitive analysis

Explore patent oppositions filed by Elkington And Fife against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Apr 2, 2026

Patent Number	Title	Applicant	Opposition Date
EP4338805	Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin Therapy	AMARIN PHARMACEUTICALS IRELAND	Feb 26, 2026
EP4342546	Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin Therapy	AMARIN PHARMACEUTICALS IRELAND	Feb 25, 2026
EP3658140	Combinations Of A 4-Pyrimidinesulfamide Derivative With Active Ingredients For The Treatment Of Endothelin Related Diseases	IDORSIA PHARMACEUTICALS	Feb 13, 2026
EP3411406	Multispecific Antigen-Binding Molecule With Improved Internalization Characteristics	GENMAB	Jan 9, 2026
EP3716979	Combination Of A 4-Pyrimidinesulfamide Derivative With An Sglt-2 Inhibitor For The Treatment Of Endothelin Related Diseases	IDORSIA PHARMACEUTICALS	Jan 8, 2026
EP3807267	Thyroid Hormone Receptor Agonists And Uses Thereof	FRONTHERA PHARMACEUTICALS	Dec 19, 2025
EP3756650	Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione	AMGEN EUROPE	Oct 1, 2025
EP4218732	Tablets Comprising Eltrombopag Olamine	NOVARTIS	Sep 9, 2025
EP3321270	Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-Olate	GILEAD SCIENCES	Sep 4, 2025
EP4233846	Pharmaceutical Formulations	GILEAD SCIENCES	Sep 4, 2025

Discover the latest PTAB cases involving Elkington And Fife, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Elkington And Fife with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Apr 2, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ELKINGTON AND FIFE	98	-	-	-
AMARIN PHARMACEUTICALS IRELAND	-	19	-	1
F HOFFMANN LA ROCHE	16	147	-	-
NOVARTIS	6	441	-	21